In Q2 FY16, the company’s consolidated revenue was at Rs 1,463 crore
The board of Jubilant Life Sciences recently met to approve the financial results for the quarter ended September 30, 2015.
In Q2 FY16, the company’s consolidated revenue was at Rs 1,463 crore, up seven per cent Y-o-Y, the pharmaceuticals revenue at Rs 747 crore, contributing 51 per cent to the overall mix. The LSI revenue was at Rs 716 crore, contributing 49 per cent to the overall mix. The international revenues was at Rs 1,054 crore, contributing 72 per cent to the overall mix. EBITDA was at Rs 325 crore, growing 137 per cent Y-o-Y with EBITDA margins at 22.2 per cent. PAT was at Rs 116 crore, with an EPS of Rs 7.27 in the quarter.
In H1 FY16 highlights, consolidated revenue was at Rs 2,922 crore, up three Y-o-Y. Pharmaceuticals revenue was at Rs 1,488 crore, contributing 51 per cent to the overall mix. The LSI revenue was at Rs 1,434 crore, contributing 49 per cent to the overall mix. International revenues was at Rs 2,110 crore, contributing 72 per cent to the overall mix. EBITDA was at Rs 658 crore, growing 129 per cent Y-o-Y with EBITDA margins at 22.5 per cent. PAT at Rs 244 crore, with an EPS of Rs 15.31.
Commenting on the company’s performance, Shyam S Bhartia, Chairman and Hari S Bhartia, Co-Chairman and Managing Director, Jubilant Life Sciences said, “Our performance in this quarter is a continuation of the good growth momentum of the last two quarters, with better earnings across both segments. Our pharma segment witnessed sustained improvement due to increase in revenues across all geographies led by growth in North America. Margins in our life science ingredients business were better, led by specialty intermediates and nutritional products. Our performance is back on track and we expect to sustain the momentum during this year.”
Comments are closed.